Ilant Health provides end-to-end, clinician-led obesity and cardiometabolic care that combines behavioral therapy, medication (GLP-1 and non-GLP-1), and surgical options within a precision-medicine model that continuously adapts treatment to individual response. The company works directly with employers and health plans to deliver measurable clinical and financial outcomes and to manage both treatment costs and total cost of care. Early results reported by Ilant show members achieve an average 15% weight loss and an average of two additional mentally healthy days per month. Ilant emphasizes data- and analytics-driven care pathways, clinician oversight, and transparent contracting for medications; it has announced direct contracting and transparent pricing through Lilly’s Employer Connect program and is working with Novo Nordisk. The company presents itself as an AI-enabled healthcare services provider that aims to move obesity care from disconnected interventions to a continuous, outcomes-focused service. Ilant has raised over $22 million to date following the $15 million Series A and is partnering with employers and payers to scale its model.

Total raised

$21M

Funding rounds

3

Latest round

Series A

Latest activity

Jun 2026